Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
FOXO4-DRI vs Humanin
An educational, source-based comparison of FOXO4-DRI and Humanin — how each peptide works, what it's researched for, and what to know before going deeper.
A D-retro-inverso peptide that disrupts the FOXO4-p53 interaction inside senescent cells, selectively triggering their apoptosis while sparing healthy cells in preclinical models.
- Senescent cell clearance
- Tissue function in aged mice
- Fibrotic disease models
- • No human trials; safety and pharmacokinetics in humans unknown.
- • Not FDA-approved.
Mitochondrial-derived peptide studied for neuroprotection and metabolism.
A 24-amino-acid peptide encoded in mitochondrial DNA. Research suggests cytoprotective effects against Alzheimer's-related toxicity, improved insulin sensitivity, and modulation of apoptotic signaling.
- Neuroprotection (Alzheimer's models)
- Insulin sensitivity
- Cardiovascular protection in animal models
- • Early-stage research.
- • No approved therapeutic use.
FOXO4-DRI vs Humanin — Key differences
- Class: FOXO4-DRI is classified as Longevity · Senolytic, while Humanin is Mitochondrial · Neuroprotection.
- Primary research focus: FOXO4-DRI — senescent cell clearance; Humanin — neuroprotection (alzheimer's models).
- Tag: Longevity · Senolytic vs Longevity.